Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K45/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/135123METHOD FOR PREPARING ALBUMIN NANOPARTICLES BASED ON FREE RADICAL OXIDATION
WO 02.07.2020
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
Appl.No PCT/CN2019/125591 Applicant HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY Inventor WANG, Jiangling
The present invention relates to the field of pharmaceutical preparations, and specifically discloses a method for preparing albumin nanoparticles based on free radical oxidation, comprising the following steps: preparing albumin aqueous solution with an albumin concentration of 1-20 mg/mL; (2) whilst stirring, adding free radical generating agent to the albumin aqueous solution, and continuing to stir and react for 1-60 min at 15-50 ℃; the free radicals generated by the free radical generating agent are used for oxidising the albumin, and the oxidised albumin molecules assemble to form albumin nanoparticles that are mainly bonded by hydrophobic action, thereby obtaining an albumin nanoparticle solution. The present invention implements improvement by means of the key reaction mechanism of the nano particle preparation method and the corresponding design of the finishing process and, compared to the prior art, can effectively solve the problems of the complexity, high cost, and high toxicity of preparing nanoparticles; the present invention has simple processes and low production costs, and is suitable for large-scale industrial production.
2.WO/2020/135318APPLICATION OF CD38 INHIBITOR IN PREPARATION OF ANTI-RHEUMATOID ARTHRITIS DRUG
WO 02.07.2020
Int.Class A61K 45/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
Appl.No PCT/CN2019/127369 Applicant HUBEI ATALENT BIOPHARMA TECHNOLOGY CO., LTD Inventor CHANG, Xiaotian
Provided is an application of a CD38 inhibitor in the preparation of an anti-rheumatoid arthritis (RA) drug. Studies have shown that the CD38+NK cell content and the ratio of CD38+NK / CD38+NKT in the blood and synovial fluid of an RA patient are increased, and such change is positively correlated with the DAS28 of the patient, indicating that CD38+NK cells and CD38+NKT cells are expected to become the therapeutic target of RA. Further research clearly shows that high levels of CD38+NK and a high ratio of CD38+NK / CD38+NKT in RA can reduce TGF-β secretion and activate the mTOR pathway of CD4+T cells in MNC, inhibiting the differentiation of CD4+T cells to differentiate Treg cells and IL-10 expression, increase the level of IFN-γ and the ratios of Thl/Th2 and Thl7/Treg, resulting in reduced anti-inflammatory and immune tolerance and exacerbating the course of RA.
3.WO/2020/138067THERAPEUTIC AGENT FOR RNA VIRAL INFECTION OBTAINED BY COMBINING PYRAZINE DERIVATIVE AND COMPOUND INCREASING AMOUNT OF PYRAZINE DERIVATIVE RIBOSE TRIPHOSPHATE BODIES IN CELL
WO 02.07.2020
Int.Class A61K 31/427
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425Thiazoles
427not condensed and containing further heterocyclic rings
Appl.No PCT/JP2019/050578 Applicant FUJIFILM TOYAMA CHEMICAL CO., LTD. Inventor KOMENO Takashi
The problem of the present invention is to provide a therapeutic agent for an RNA viral infection which comprises a novel combination of a pyrazine derivative and a specified compound and which is exhibits an effect against an RNA virus, and to provide a therapeutic agent for an RNA viral infection which comprises the combination of the pyrazine derivative and the specified compound and which can simultaneously potentiate antiviral activity against a plurality of RNA viruses. The present invention provides a therapeutic agent for an RNA viral infection obtained by combining a pyrazine derivative or a salt thereof, and a compound which increases the amount of pyrazine derivative ribose triphosphate bodies in a cell.
4.WO/2020/138499ALKYL-SUBSTITUTED COMPOUND
WO 02.07.2020
Int.Class A61K 31/407
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
407condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
Appl.No PCT/JP2019/051620 Applicant SUMITOMO DAINIPPON PHARMA CO., LTD. Inventor KOIKE Sachiko
The purpose of the present invention is to provide a novel compound that has an excellent β-lactamase inhibitory activity. The present invention provides: a compound that has an excellent β-lactamase inhibitory activity and is represented by formula (1a), (1b) or (11); or a pharmaceutically acceptable salt thereof. The compound provides a prophylactic or therapeutic agent that is useful for bacterial infection when used in combination with a β-lactam drug or used alone. The present invention also provides a prophylactic or therapeutic agent that is useful for treating a variety of diseases in combination with a β-lactam drug.
5.WO/2020/139240PHARMACEUTICS COMPOSITION PROVIDING EXTENDED RELEASE COMPRISING IBUPROFEN, PSEUDOEPHEDRINE AND ERDOSTEINE
WO 02.07.2020
Int.Class A61K 31/192
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
192having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
Appl.No PCT/TR2019/051014 Applicant ATATÜRK ÜNİVERSİTESİ BİLİMSEL ARAŞTIRMA PROJELERİ BİRİMİ Inventor ATILLA, Alptuğ
Invention relates to a pharmaceutics composition comprising ibuprofen, pseudoephedrine HCI and Erdosteine for treatment of upper respiratory infections. The invention particularly relates to an oral pharmaceutics composition comprising ibuprofen, pseudoephedrine HCI and Erdosteine as a new combination for treatment of diseases such as temperature, asthenia, muscle and headache, severe coughing arising from mucus and runny nose occurring after rhinitis, acute rhino sinusitis, severe colds or influenza.
6.WO/2020/136648CANNABIDIOLIC ACID ESTERS FOR COSMETIC OR EDIBLE COMPOSITIONS
WO 02.07.2020
Int.Class A61K 31/192
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
192having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
Appl.No PCT/IL2019/051408 Applicant EPM GROUP INC. Inventor SWISA, Reshef
The present invention provides cosmetic or edible compositions comprising a cannabinoid component, wherein the cannabinoid component comprises a cannabidiolic acid (CBDA) ester alone or in combination with one or more cannabinoid compound(s), and a physiologically acceptable carrier, excipient or diluent, and uses thereof for improving appearance, well-being and/or general health.
7.WO/2020/139044NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR ENHANCING ANTICANCER ACTIVITY
WO 02.07.2020
Int.Class A61K 31/4985
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
Appl.No PCT/KR2019/018660 Applicant HOLOSMEDIC Inventor PARK, Ki Cheong
The present invention relates to a novel compound and a pharmaceutical composition comprising same for enhancing anticancer activity, and more specifically, by comprising a compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof, the anticancer activity of an anticancer agent or radiation can be enhanced, and by suppressing the proliferation of cancer cells and inducing apoptosis thereof, cancer can be treated effectively. [Chemical formula 1] In the chemical formula 1: n is an integer of 0 to 4; R1 is hydrogen, C1-C10 alkyl, or aryl(C1-C4)alkyl; R3 is C1-C6 alkyl, wherein the R3, if a plurality thereof is present, are identical or different from each other; L1 is a direct bond or C1-C6 alkylene; R2 is hydrogen, C1-C10 alkyl, or aryl(C1-C4)alkyl; and R4 is hydrogen, C1-C4 alkyl, C3-C8 cycloalkyl, or aryl(C1-C4)alkyl, or R2 and R4 are connected to each other, forming a 4- to 7-membered ring.
8.WO/2020/139897SILENCING TGF-BETA 1 AND COX2 USING SIRNAS DELIVERED IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS TO TREAT CANCER
WO 02.07.2020
Int.Class C07H 21/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
04with deoxyribosyl as saccharide radical
Appl.No PCT/US2019/068499 Applicant SIRNAOMICS, INC. Inventor EVANS, David M.
The present invention provides certain pharmaceutical molecules and compositions and methods of using them to treat cancer. The molecules are small interfering RNA (siRNA) molecules that inhibit TGF-beta 1 and Cox2 in humans and other mammals, which are used alone or in combination with immune checkpoint inhibitors, to treat cancer.
9.WO/2020/138430THERAPEUTIC DRUG FOR DISEASE ACCOMPANIED BY DISORDERS IN RETINAL SYSTEM CELLS OR RETINAL TISSUE
WO 02.07.2020
Int.Class A61K 31/573
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
57substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
573substituted in position 21, e.g. cortisone, dexamethasone, prednisone
Appl.No PCT/JP2019/051468 Applicant RIKEN Inventor SUGITA Sunao
The present invention pertains to a therapeutic drug for diseases accompanied by disorders in retinal system cells or a retinal tissue, the drug containing a non-autologous retinal tissue having a steric structure. The intended patients for the therapeutic drug administration are those who are affected with diseases accompanied by disorders in retinal system cells or a retinal tissue and who would not receive systemic administration of an immune-suppressive agent used for the purpose of preventing any rejection reaction caused by transplant for at least a month after the therapeutic drug was administered.
10.WO/2020/138570NOVEL RUTHENIUM COMPLEX COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER
WO 02.07.2020
Int.Class C07F 15/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
FACYCLIC, CARBOCYCLIC, OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
15Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
Appl.No PCT/KR2018/016898 Applicant SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION Inventor SONG, Joon Myong
The present invention relates to a novel ruthenium complex compound, a preparation method therefor, and a pharmaceutical composition comprising same as an active ingredient for prevention or treatment of cancer. A novel Ru complex compound according to the present invention exhibits not only an excellent killing effect on cancer cells, but also can outstandingly inhibit resistance mechanisms of cancer stem cells. Thus, the complex compound can be effectively used as an active ingredient in a pharmaceutical composition for prevention or treatment of cancer or a composition for inhibiting resistance to anticancer agents, and can be used in combination of other chemotherapeutic agents in a pharmaceutical composition for prevention or treatment of cancer, which solves conventional problems of resistance to anticancer agents.